Dova Pharmaceuticals is a clinical-stage pharmaceutical company focused on acquiring, developing, and marketing treatments for thrombocytopenia, a disorder characterized by a low blood platelet count. The Company's major drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist.
Dova has recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures.
Net income (FY, 2016)
EBIT (FY, 2016)
Market capitalization (15-Mar-2019)
Closing stock price (15-Mar-2019)
General and administrative expense
Operating expense total
Cash From Operating Activities
Cash From Financing Activities
When was Dova Pharmaceuticals founded?
Dova Pharmaceuticals was founded in 2016.
Who are Dova Pharmaceuticals key executives?
Dova Pharmaceuticals's key executives are Alex Sapir, Mark Hahn and Kevin Laliberte.
How many employees does Dova Pharmaceuticals have?
Dova Pharmaceuticals has 7 employees.
Who are Dova Pharmaceuticals competitors?
Competitors of Dova Pharmaceuticals include Vitality Biopharma, Opiant Pharmaceuticals and IntelGenx.
Where is Dova Pharmaceuticals headquarters?
Dova Pharmaceuticals headquarters is located at 240 Leigh Farm Rd #245, Durham.
Where are Dova Pharmaceuticals offices?
Dova Pharmaceuticals has an office in Durham.
How many offices does Dova Pharmaceuticals have?
Dova Pharmaceuticals has 1 office.